- Home
- IMNM
IMNM
Immunome Inc.
as 02-21-2025 4:00pm EST
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.
| Founded: | 2006 | Country: | United States |
| Employees: | 105 | City: | BOTHELL |
| Market Cap: | 806.1M | IPO Year: | 2020 |
| Target Price: | $28.60 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.69 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.97 - $30.96 | Next Earning Date: | 03-27-2025 |
| Revenue: | $10,129,000 | Revenue Growth: | -0.62% |
| Revenue Growth (this year): | -31.5% | Revenue Growth (next year): | -67.09% |
Stock Insider Trading Activity of Immunome Inc. (IMNM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| SIEGALL CLAY B | IMNM | President and CEO | Jan 31 '25 | Buy | $7.75 | 150,000 | $1,162,500.00 | 669,636 |
Latest Immunome Inc. News
IMNM Breaking Stock News: Dive into IMNM Ticker-Specific Updates for Smart Investing
Business Wire
16 days ago
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Simply Wall St.
18 days ago
Insider Stock Buying Reaches US$2.82m On Immunome
MT Newswires
22 days ago
Immunome Closes Public Offering of Shares
Business Wire
22 days ago
Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
MT Newswires
23 days ago
Immunome Prices $150 Million Stock Offering
Business Wire
24 days ago
Immunome Announces Pricing of Upsized Public Offering of Common Stock
Business Wire
24 days ago
Immunome Announces Proposed Public Offering of Common Stock
Business Wire
a month ago
Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
Compare IMNM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMNM Immunome Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.